Alpha Cognition Inc (ACOG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.86 (+0.11%), Market cap $0.13B, 52-week low–high $4.50 ~ $11.24.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, includin
Financial statements, price targets, institutional (13F) holdings and related news for Alpha Cognition Inc are updated in real time on BlackAll Trade.
Alpha Cognition Inc trades at $8.86 (+0.11%). Real-time quotes and charts are available on BlackAll Trade.
Alpha Cognition Inc has a market cap of about $0.13B.
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commer